Contract Research And Manufacturing Services (crams)

Jump to

Navin Fluorine: Input challenges remain, but 3 factors make it ripe for accumulation

The management expects raw material prices to remain elevated in the near- to medium-term.
See more upside for Biocon post Syngene listing: Phillipcap

Biocon plans to list its research arm Syngene and on Wednesday filed prospectus with the market regulator Sebi. It aims to raise around Rs 600 crore.
Dishman Pharma eyes over 15% topline growth going forward

Managing director of Dishman Pharmaceuticals, JR Vyas expects the topline growth to be 15% or even more going forward. He also added that the bottomline will grow in the second half too.
Dishman Pharma eyes 15% growth in FY12

VVS Murthy, CFO of Dishman Pharma, in an interview with CNBC-TV18's Latha Venkatesh and Gautam Broker, spoke about the recent report by one of the brokerages Indiabulls Securities, which downgraded the company's stocks and the road ahead.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Contract Research And Manufacturing Services (crams)

Navin Fluorine: Input challenges remain, but 3 factors make it ripe for accumulation

See more upside for Biocon post Syngene listing: Phillipcap

Dishman Pharma eyes over 15% topline growth going forward

Dishman Pharma eyes 15% growth in FY12